Navigation Links
Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
Date:4/28/2009

Indian Oncologists Are Starting to Embrace Use of Targeted Agents Despite Their High Cost, According to a Report from Decision Resources

WALTHAM, Mass., April 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Sanofi-Aventis' Eloxatin, Indian brand/generics (oxaliplatin) and Roche/Chugai's Xeloda, Indian brand/generics (capecitabine) will dominate the Indian colorectal cancer drug market through 2013. However, as a result of the increased use of targeted agents and rapid growth of the Indian colorectal cancer drug market the combined market share of these two drugs will fall from 67 percent in 2008 to 52 percent in 2013.

The new Emerging Markets report entitled Colorectal Cancer in India also finds that Indian oncologists are starting to embrace use of targeted agents such as Roche/Chugai's Avastin (bevacizumab) and Merck KGaA/Bristol-Myers Squibb's Erbitux (cetuximab) despite their high cost. Growth of these agents and the launch of Amgen's Vectibix (panitumumab) will ensure that sales of targeted agents rise from $3.1 million in 2008 to $13.5 million in 2013.

"The increased use of targeted agents like Avastin and Erbitux is due to the increasing wealth and urbanization among India's population and because their efficacy and toxicity are superior to those of conventional therapies," stated Marcus Hoyle, analyst at Decision Resources.

About Emerging Markets Reports

Emerging Markets is a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
2. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
3. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
4. Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
5. Sanofi-aventis Partners with the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
6. Sanofi-aventis Delivers 2008 Results Above Guidance
7. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
8. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
9. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
10. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
11. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: